Navigation Links
First U.S. Patients Treated in PneumRx RENEW Pivotal Study for Treatment of Severe Emphysema
Date:2/25/2013

ive devices designed to treat emphysema, the RePneu LVRC is intended to treat a broad range of emphysema patients, including those with heterogeneous and homogeneous disease, in both upper and lower lobes, and it performs independently of collateral ventilation, a common condition in emphysema patients.

The RENEW Study began enrolling patients in the European sites, which are experienced in the technique, late last year.  Up to 315 patients in over 25 medical centers across North America, plus centers in the Netherlands, UK and Germany, will participate in the RENEW Study.  "Bringing relief to the millions of emphysema sufferers was a significant motivation in founding PneumRx, so it is particularly meaningful to me that we have begun treating people with this debilitating disease here at home.  We look forward to submitting the pivotal trial results in support of a PMA application and eventually offering the benefits of LVRC treatment to patients throughout the U.S." stated Erin McGurk , President and CEO of PneumRx.

Qualifying patients must have been clinically diagnosed with severe emphysema and be experiencing increasing difficulty with simple daily tasks. Patients must have stopped smoking for at least eight weeks and must have completed a pulmonary rehabilitation program prior to enrollment.

Although the RePneu LVRC is investigational in the United States and not yet approved for commercial use by the FDA, the device has a CE Mark and has been used in Europe for the treatment of severe emphysema since 2008.

For more information about the RePneu LVRC and the RENEW study, visit www.pneumrx.com or http://www.clinicaltrials.gov/ct2/
'/>"/>

SOURCE PneumRx, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Thoratec Schedules First Quarter Conference Call, Webcast
3. Watson to Host Conference Call and Webcast to Discuss First Quarter 2012 Earnings
4. CVS Caremark Corporation to Hold First Quarter 2012 Conference Call
5. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
6. Alexza to Announce 2012 First Quarter Financial Results on Thursday, May 10, 2012
7. 3SBio Inc. Schedules Unaudited First Quarter 2012 Results
8. Insmed to Host 2012 First Quarter Earnings Conference Call
9. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
10. Henry Schein to Webcast First Quarter 2012 Conference Call Tuesday, May 8, at 10:00 a.m. EDT
11. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... DUBLIN , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... of Directors has approved a share repurchase program. The ... $300 million of Mallinckrodt plc ordinary shares. ... opportunities remain top priorities as we continue to pursue ...
(Date:1/23/2015)... Jan. 23, 2015 Tianyin Pharmaceutical Inc. (NYSE Amex: ... in the development and sale of patented biopharmaceutical medicine, ... pharmaceutical ingredients (API) today announced the business and development ... 1. Following the September 2014 JCM application ...
(Date:1/22/2015)... UPI ), a medical device company that develops, manufactures ... today reported financial results for the fiscal 2015 third ... the Company,s Urgent ®  PC Neuromodulation System grew 14.5% ... compared to $3.9 million in the third quarter of ...
Breaking Medicine Technology:Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18
... 2007 - ImmunoGen, Inc.,(Nasdaq: IMGN), a biopharmaceutical company ... (TAP),technology, today announced that clinical findings for three,different ... are to be,reported at the 43rd American Society ... June 1-5, 2007 in Chicago, IL., Trastuzumab-DM1 (abstract ...
... 2007 - GTx, Inc., (NASDAQ:,GTXI) announced today that ... clinical trial of Ostarine(TM) and from the ongoing ... for the treatment of multiple side effects of ... upcoming 2007,Annual Meeting of the American Society of ...
Cached Medicine Technology:ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds,for Solid Tumors Are to be Reported at ASCO 2ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds,for Solid Tumors Are to be Reported at ASCO 3GTx Announces Presentation of Ostarine and Acapodene Data at 2007,ASCO Annual Meeting 2GTx Announces Presentation of Ostarine and Acapodene Data at 2007,ASCO Annual Meeting 3
(Date:1/22/2015)... EAGAN, Minn. (PRWEB) January 22, 2015 Blue ... discover those Minnesotans who exemplify what it means to “Live ... a chance for people to share their stories about how ... adversity or simply inspired others by living in the moment. ...
(Date:1/22/2015)... 2015 Thousand of GranuFlo lawsuits ( ... its GranuFlo and NaturaLyte dialysis concentrates continue to move ... District Court, District of Massachusetts, Bernstein Liebhard LLP reports. ... has remanded a case filed by the state of ...
(Date:1/22/2015)... A study recently published in ... Medicine & Science in Sports & Exercise shows ... reduce gastrointestinal (GI) problems associated with physical strain ... the double-blind, placebo-controlled study took 10 grams of ...
(Date:1/22/2015)... 2015 Payday lending practices in four ... cause financial distress to the states that permit them, ... University’s Center on Race and Wealth. , While they ... payday loans at the same time substantially depress economic ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Lower-Auto-Insurance.com has released a ... kit in a car for reducing the costs of an ... will also be able to get lower prices for their vehicle ... an important role in determining policy costs. Because of this, ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
... from the University of Melbourne and La Trobe University have ... grains such as wheat and barley. With the stress being ... that this discovery would allow them to manipulate the fibre ... the production of beta-glucans, which is a major part of ...
... is to soon go on Phase I trial. It maybe ... Biocon, Ms.Kiran Mazumdar Shaw. ,Ms.Shaw was speaking ... Foundation(MDRF) on awards for innovation and R&D.// There are close ... to diabetes should always bear this in mind and develop ...
... underwent a successful life-changing operation in India and returned home ... being// overweight. ,David Rogers, 62, from Abbeydale, Worcestershire, ... for the double hip and knee replacements that he desperately ... was about 37 kg too heavy for the surgery. ...
... two new genes found with breast tumors can predict the ... In the report appearing in he April 1 issue of ... identify women at risk for an early relapse of breast ... previously discovered as a potential marker of relapse in hormone-receptor ...
... the peels of fruits and vegetables, which are thrown away ... better to have a second thought next time, when you ... and keeps you young. ,As reported in foodconsumer.org ... the United States to $2.7 billion in 2003. Top of ...
... have bettered among the teenagers and young adults (TYAs) in ... than in those where people have to pay for their ... system of health insurance for all, regardless of age, meant ... than they were in the USA. ,Prof ...
Cached Medicine News:Health News:Overweight Briton Underwent Successful Surgery In India Being Denied By NHS 2Health News:Easy Access To Healthcare Services Essential For Better Survival Rates 2Health News:Easy Access To Healthcare Services Essential For Better Survival Rates 3
... third-generation immunoassay system combines continuous ... processing with a broad testing ... higher volume clinical laboratories to ... tests simultaneously, as well as ...
... ADVIA Centaur delivers a new ... provides the flexibility to integrate ... now and in the future. ... comprehensive disease-focused menu of immunoassays ...
... Synchron LXi 725 clinical system combines ... accurate immunoassay testing capabilities, innovative data ... a single platform. After tests are ... for optimal quality assurance. If reflex ...
...
Medicine Products: